Gliclazide-based agents are used for the supportive treatment of type 2 diabetes mellitus, in which insulin molecules are produced. This substance is a second generation sulfonylurea derivative.
General characteristics
The medicine "Glidiab MV 30" is considered the Russian analogue of the French drug "Diabeton MV". Produced by the Akrikhin Chemical and Pharmaceutical Plant in the Moscow Region.
The drug refers to oral hypoglycemic agents in tablet form with a modified release. The color of their structure is white or cream, there may be marble inclusions. Tablets resemble flat cylinders with a chamfer.
Retail packaging is a pack. It may contain 30 or 60 tablets packed in blister strips.
Composition
Unlike the drug "Diabeton MV" with a dose of 0.060 g of gliclazide, the drug "Glidiab MV" has twice the amount of the identical active ingredientbelow, which is 0.030g.
Inactive tablet components include hydroxypropyl methylcellulose, aerosil molecules, magnesium stearate, microcrystalline cellulose.
There is also the drug "Glidiab" with the usual release of the active substance. The dosage in one tablet is 0.08 g of gliclazide.
How it works
The instructions for use attached to the Glidiab MB medication describe the action of gliclazide, which stimulates insulin secretion in β-cells located in the pancreas.
Under the influence of tablets, the insulin secretory activity of glucose molecules increases, and peripheral tissues become more sensitive to the insulin hormone.
Muscle glycogen synthetase, being an intracellular enzyme, is more effective. There is a decrease in the interval from the start of eating to the release of the hormone. Insulin secretion is restored at an early peak, which distinguishes gliclazide from other sulfonylurea precursors, the action of which occurs at the second stage. Decreased postprandial glucose levels.
Microcirculation improves due to the association and adhesion of platelet cells, normalization of the permeability of the vascular wall, reducing the development of microthrombotic and atherosclerotic processes, restoring the reactions of natural dissolution of blood clots. The possibility of response of receptor formations in vessels to adrenaline molecules decreases.
The drug is able to slow down diabetic retinopathy at the non-proliferative stage. Long-term treatment with this drug in conditions of diabetic damage to the constituent parts of the kidneys responsible for filtration can significantly reduce the excretion of proteins in the urine.
The drug does not increase body weight, but on the contrary, it reduces due to the effect on the early stage of insulin release. It does not provoke increased insulinemia.
What is used for
Doctors recommend using the drug for high blood sugar of the second degree. Treatment is carried out with insufficient effect from diet and moderate exercise.
For the drug "Glidiab MB" indications are related to the prevention of deterioration in diabetic disorders characterized by nephropathy, retinopathy, myocardial infarction and stroke.
How to use
The dosage of the drug is selected for each patient separately, taking into account the manifestations of the disease, the glucose concentration on an empty stomach and 120 minutes after eating.
For the drug "Glidiab MV" instructions for use prescribes a daily initial dose of 0.03 g, which is equivalent to one tablet. This concentration is indicated for elderly patients after 65 years of age. The medication is used orally, one tablet in the morning, when breakfast is taken.
If necessary, the dosage is increased every two weeks. A maximum of one day is allowed to take about 0.120 g, which corresponds to 4 tablets.
Medication "Glidiab MV" is used instead of the regular release drug of the same name, using 1-4 tablets per day.
It is combined with a hypoglycemic agent based on biguanide, an alpha-glucosidase inhibitor of insulin molecules.
In case of impaired renal function of a mild or moderate nature, when the rate of excretion of creatinine is not more than 0.080 liters per minute, the dosage is not reduced.
When not to take
Tablets "Glidiab MV" instructions for use do not recommend using in the first form of diabetes mellitus disease, with an increase in ketones in the urine, with gastric paresis, with hyperosmolar, diabetic coma and precoma, with major surgical operations and burn lesions, traumatic processes when insulin treatment is needed.
Severe impairment of hepatic or renal function, bowel obstruction, changes in digestion of food, development of a hypoglycemic state are contraindicated.
Do not use the drug for fever, leukopenia, pregnancy, breastfeeding and excessive intolerance to the ingredients of the drug.
Caution is required when administering the drug, special supervision and dosage selection for patients with alcohol dependence and thyroid disorders.
Features of treatment
To the drug "Glidiab MV" instructions for use indicate the need to combine it with a low-calorie diet, including a low carbohydratecontent. Regular monitoring of the concentration of glucose in the bloodstream is required in the morning before and after meals.
If there were surgical interventions or decompensation of the diabetic condition, insulin administration is possible.
There are warnings about the occurrence of a hypoglycemic process with the use of ethyl alcohol, non-steroidal anti-inflammatory substances and lack of nutrition. Drinking alcohol can cause a disulfiram-like syndrome, with headaches and stomachaches, and possible nausea and vomiting.
The dosage of the medicine should be adjusted during physical or emotional stress and at untimely meals. The elderly, patients with an unbalanced or poor diet, debilitated patients who suffer from adrenal insufficiency, are especially sensitive to the influence of the remedy. pituitary system.
At the initial stages of using the drug when choosing a dosage, if there is a predisposition to a hypoglycemic crisis, you do not need to perform actions that require increased attention and a quick psychomotor reaction.
Adverse reactions
To the remedy "Glidiab MV" the instruction includes information about violations in the endocrine organs in case of failure in the mode of taking pills and in case of malnutrition. Usually, a decrease in the level of glucose in the bloodstream causes pain in the head, tired, hungry, helpless, anxious well-being, instant weakness, aggression, weakconcentration, depression. There are also changes in visual perception, tremors, sensory and convulsive disorder, dizziness, hypersomnia, shallow breathing, decreased heart rate.
Digestive organs malfunction in the form of malabsorption, nausea, diarrhea, anorexic lack of appetite, dysfunction of liver cells, cholestatic jaundice, increased efficiency of transaminase enzymes.
Undesirable processes in the hematopoietic system are associated with a decrease in hemoglobin, the number of platelet and leukocyte cells.
The drug can cause allergic manifestations in the form of itching, urticaria, maculo-papular rash.
Overinjection
The instructions for use attached to the Glidiab MV product warns against overdose, which is expressed by a decrease in glucose concentration in the blood plasma. With a strong excess of the drug, a hypoglycemic coma may develop.
To eliminate it, a person is given to eat some well-absorbed carbohydrates, for example, a sugar cube. When a person is unconscious, a 40% dextrose or glucose solution is injected into a vein, and glucagon is injected into the muscle in an amount of 1 mg. If the patient wakes up, then he is forced to eat well-absorbed carbohydrates to avoid a recurrence of a hypoglycemic attack.
Combination with drugs
The hypoglycemic activity of the drug "Glidiab MB 30 mg" can be enhanced by parallel administrationan angiotensin-converting and monoamine oxidase-type enzyme inhibitor, a blocker of beta-adrenergic and H2-histamine-dependent receptor formations based on cimetidine, antifungal miconazole and fluconazole drugs, non-steroidal anti-inflammatory substances phenylbutazone, indomethacin, diclofenac.
The effect of the effects of tablets is increased with the help of clofibrates and bezafibrates, anti-tuberculosis drugs from the ethionamide group, salicylates, indirect anticoagulant compounds of the coumarin structure, anabolic steroids, cyclophosphamides, chloramphenicols, sulfonamides with a prolonged effect.
The drug reduces blood sugar more effectively when using tubular release blockers, ethyl alcohol, acarbose, biguanide, insulin.
The decrease in the hypoglycemic effect of tablets is caused by barbiturates, drugs based on epinephrine, clonidine, terbutaline, ritodrine, salbutamol, phenytoin, carbonic anhydrase enzyme inhibitors such as acetazolamide, thiazide diuretics, thyroid hormones, lithium-containing drugs, estrogen remedies.
Ethyl alcohol molecules are able to act on gliclazide with the occurrence of a disulfiram-like process.
The active component of the tablets causes untimely depolarization and contraction of the ventricles of the myocardial muscle when combined with cardiac glycosides.
Beta-blockers, clonidine, reserpine, guanethidine drugs mask clinical hypoglycemia.
Opinionspatients
Important is not only the instructions for use attached to the medication "Glidiab MV". Reviews tell about what exactly patients think about the effectiveness of the drug. This tool helps many patients to reduce the concentration of glucose to normal values, and in combination with the diet changes the patient's lifestyle.
People note that the positive feature of the tablets is their convenient use in the morning. During the day, you can not remember the need for treatment.
Reviews can also be heard on the drug "Glidiab MV" of a negative nature, associated with the inefficiency of this remedy. This usually happens when the dosage is incorrect, when a small amount of medicine is prescribed.
